



FOR IMMEDIATE RELEASE:

EYEGATE PHARMA APPOINTS BOARD POSITIONS

Paul Chaney to Serve as Chairman and Morton Goldberg, M.D., Appointed Director

Waltham, MA – October 22, 2008 – EyeGate Pharma, a specialty pharmaceutical company using iontophoresis technology to safely and non-invasively deliver therapeutics to treat serious ocular diseases, today announced the board appointments of Mr. Paul G. Chaney as Chairman of the Board, and Morton Goldberg, M.D., as Director. Mr. Chaney is currently a consultant at Eyetech, which recently spun out of (OSI) Eyetech. Mr. Chaney was Executive Vice President of OSI Pharmaceuticals (Nasdaq: OSIP) and President of (OSI) Eyetech, OSI's eye care subsidiary. Dr. Morton F. Goldberg is a Joseph E. Green Professor of Ophthalmology at the Wilmer Eye Institute, Johns Hopkins University School of Medicine⁽¹⁾.

Stephen From, President and Chief Executive Officer of EyeGate Pharma, commented, "Paul has been a valued member of the Board since joining last year, and his leadership as the newly appointed Chairman will help provide EyeGate with the strategic counsel and experience to build upon our successful clinical operations in ophthalmology. With Paul having the unique perspective and understanding of our business as a current Board member, and his depth of experience in ophthalmology development and product launch, he is the ideal candidate to help our management team prepare for the potential commercialization of the EyeGate[®] II Ocular Delivery System."

Mr. Chaney has more than 25 years of experience in the pharmaceutical industry. He was formerly a core member of the OSI Executive Management Committee, where he was responsible for all business functions including R&D, sales, marketing, medical affairs and business development. Prior to the merger of Eyetech with OSI, Mr. Chaney served as Chief Operating Officer of Eyetech where he was responsible for preparing the organization for the launch of MACUGEN[®], the first FDA approved anti-VEGF inhibitor to treat wet age-related macular degeneration (AMD). Mr. Chaney presided over all of the commercial functions critical to the MACUGEN[®] launch, achieving first year sales of \$185 million, the best first-year sales performance in ophthalmology history at the time.

-more-

(1) Participation by Board Member does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System

Mr. Chaney also held a variety of senior management positions at Pharmacia Corporation, a pharmaceutical company acquired by Pfizer in April 2003. At Pharmacia, he was responsible for the launch of a number of leading ophthalmic products, including Tecnis[®], Healon5[®], Xalatan[®] and Xalcom[®].

Dr. Morton F. Goldberg joins EyeGate's Board of Directors in addition to his current position at The Wilmer Eye Institute at Johns Hopkins University School of Medicine. Dr. Goldberg was also Director of the Department of Ophthalmology at The Wilmer Eye Institute from 1989 to 2003. Before becoming a Professor at Johns Hopkins, he was a Professor and head of the Department of Ophthalmology at the University of Illinois in Chicago for nearly 20 years.

Stephen From also commented, "Morton is a great addition to our Board and to the Company, providing us with invaluable insight and guidance from a physician and patient perspective. With over 30 years of experience in leading academic institutions such as the Wilmer Eye Institute, where he is Joseph E. Green Professor of Ophthalmology, he has a deep understanding of the challenges and opportunities in ophthalmic research and development. As a Board member, Morton is already a valuable resource, providing additional experience and leadership to help guide EyeGate into its next stages of clinical development."

Dr. Goldberg trained at Johns Hopkins as a resident and chief resident, and holds a joint appointment at the Applied Physics Laboratory. He is also a past President of the Association for Research in Vision and Ophthalmology, the Macula Society, and the Association of University Professors of Ophthalmology. Dr. Goldberg received his undergraduate degree from Harvard College and his M.D. from Harvard Medical School.

In addition to Mr. Chaney and Dr. Goldberg, EyeGate Pharma's Board members include Directors: Alain Maiore (General Partner of Ventech Partners), J. Sebastien Cleiftie (Investment Manager of Innoven Partenaires), Thomas E. Hancock (Principal of Nexus Medical Partners), Praveen Tyle (Senior Vice President/Global Head Research & Development at Novartis), Michael Mullen (Managing Director and Founder of Tarvos Capital Management, LLC), and Stephen From (President and CEO of EyeGate Pharma).

About EyeGate Pharma

EyeGate Pharma has recently initiated a Phase II clinical study in acute anterior uveitis designed to assess the safety and tolerability of the non-invasive EyeGate[®] II Ocular Drug Delivery System

-more-

EyeGate Pharma News:

Page 2

and plans to initiate an additional Phase II clinical trial with EGP-437 in dry eye later in 2008. EyeGate was founded in 1998 with technology licensed from Bascom Palmer Eye Institute at the University of Miami. EyeGate's transscleral (white membrane of the eye) iontophoresis delivery platform, the EyeGate® II Delivery System, was developed to safely deliver a wide range of therapeutics to both the anterior (front) and posterior (back) chambers of the eye. For more information, please visit www.eyegatepharma.com.

#

[Editors Note: Photos available upon request]

Contact:

Lisa Rivero

LaVoie Group

978-745-4200 X106

lrivero@lavoigroup.com

(1) Participation by Board Member does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System